Enovis (NYSE:ENOV – Get Rating) and Coloplast A/S (OTCMKTS:CLPBY – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Earnings and Valuation
This table compares Enovis and Coloplast A/S's gross revenue, earnings per share and valuation.
Get
Enovis alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Enovis | $3.85 billion | 0.88 | $71.66 million | $0.48 | 131.19 |
| Coloplast A/S | $2.76 billion | 9.37 | $585.21 million | $0.28 | 42.79 |
Coloplast A/S has lower revenue, but higher earnings than Enovis. Coloplast A/S is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enovis and Coloplast A/S's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Enovis | 0.94% | 4.46% | 2.78% |
| Coloplast A/S | 21.62% | 69.30% | 33.77% |
Insider & Institutional Ownership
96.7% of Enovis shares are held by institutional investors. Comparatively, 0.1% of Coloplast A/S shares are held by institutional investors. 8.3% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Enovis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Enovis and Coloplast A/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Enovis | 0 | 2 | 7 | 0 | 2.78 |
| Coloplast A/S | 1 | 2 | 2 | 0 | 2.20 |
Enovis presently has a consensus target price of $63.50, suggesting a potential upside of 0.84%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Coloplast A/S.
Summary
Enovis beats Coloplast A/S on 9 of the 14 factors compared between the two stocks.
About Enovis
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
About Coloplast A/S
(Get Rating)
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
